EVO — Evotec SE

Summary of EVO Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenues: Increased by EUR 32.1 million (14.5%) to EUR 253.3 million; full-year revenues decreased by EUR 8.6 million (1.1%) to EUR 788.4 million.
• Constant Currency Growth: Q4 revenues grew by 21%, and full-year revenues grew by 1.7%.
• Segment Performance:
  • Discovery and Preclinical Development (D&PD): Q4 revenues declined by EUR 27.3 million (16.6%) to EUR 137.1 million; full-year revenues down by EUR 82.5 million (13.5%).
  • Just-Evotec Biologics (JEB): Q4 revenues surged by EUR 59.4 million (104.2%) to EUR 116.6 million; full-year revenues increased by EUR 73.8 million (39.8%) to EUR 259.4 million, driven by the Sandoz partnership.
• Adjusted EBITDA: Q4 adjusted EBITDA rose by EUR 29.5 million (103.6%) to EUR 58 million; full-year adjusted EBITDA increased by EUR 18.5 million (81.9%) to EUR 41.1 million.
• Cash Position: Ended 2025 with EUR 476 million in cash liquidity and no active financial covenants.

2. Strategic Updates and Business Highlights

• New Strategy: Launched a strategy focusing on scientific leadership, operational excellence, and better monetization of Just-Evotec Biologics.
• Cost Savings: Achieved over EUR 60 million in annualized cost savings and reduced capital expenditure by approximately 60%.
• Horizon Initiative: Announced a comprehensive transformation of operations, including site reductions and workforce optimization, aimed at achieving EUR 75 million in structural run rate savings by the end of 2027.
• Partnerships: Significant advancements in collaborations with Bristol Myers Squibb (BMS) and Sandoz, including milestone payments and the initiation of clinical studies.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected group revenues of EUR 700 million to EUR 780 million; adjusted EBITDA projected to be EUR 0 million to EUR 40 million.
• Market Recovery: Anticipated recovery in the second half of 2026, driven by strategic partnerships and improved market conditions.
• D&PD Segment: Expected low single-digit revenue growth in the second half of 2026, with a focus on strategic deals.
• Long-term Goals: Aim for group revenues exceeding EUR 1 billion by 2030, with an adjusted EBITDA margin reaching 20% by 2028.

4. Bad News, Challenges, or Points of Concern

• Revenue Declines: Full-year revenue decline in D&PD due to challenging early-stage biotech funding and unfavorable foreign exchange impacts.
• Operational Risks: Potential risks associated with the Horizon initiative, including workforce reductions and site closures, which could disrupt ongoing customer relationships.
• BMS Collaboration: Expected high single-digit revenue decline from BMS in 2026, indicating a trough year for this significant partnership.

5. Notable Q&A Insights

• Growth in JEB: Non-Sandoz, non-Department of War revenues expected to constitute about 50% of JEB by the end of 2026, up from approximately 30% in 2025.
• BMS Future Structure: Shift towards more milestone and royalty-based remuneration in the BMS collaboration is anticipated.
• Market Dynamics: Improvement in order patterns attributed to both internal commercial efforts and a recovering biotech funding landscape.
• AI Integration: Recognition of AI's role in enhancing drug discovery processes and potential growth opportunities in the JEB segment.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A, providing a comprehensive overview of Evotec's performance and outlook.